- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01226992
Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin
Phase II/III Randomized Controlled Trial of Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin for Recurrent Clostridium Difficile Infection (CDI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed trial is a single-centre, phase II/III, open, parallel-group, randomized controlled trial. To have an evaluable population of 114 participants and assuming a 20% loss to follow-up, approximately 146 patients will be randomized in a 1:1 ratio to receive either approximately 2 weeks of oral vancomycin followed by a single fecal transplant via enema (hereon referred to as the "fecal transplant arm") or a 6-week taper of oral vancomycin (hereon referred to as the "vancomycin taper arm"). The 2 weeks of vancomycin pre-treatment in the fecal transplant arm will allow for a fecal transplant donor to be screened for potentially transmissible infectious diseases (clinically and through blood and stool tests), in order to ensure appropriateness and safety of donation.
If patients fail treatment during the follow-up period of 120 days, they will be offered the opportunity to cross over to the alternate treatment arm. Those who cross over will be followed for an additional 120 days from the second intervention.
Participants will be assessed clinically for recurrence in CDI symptoms and adverse events at the following time points after the intervention: 4 days, 7 days, 3 weeks, 6 weeks, 12 weeks and 16 weeks. All recurrences of CDI symptoms will be investigated with C. difficile laboratory testing to confirm the etiology of these symptoms.
Analysis will be intention to treat. An interim analysis may take place after completion of follow-up of 30 patients. This interim analysis is meant to establish the safety and feasibility of the study, not measure efficacy. Although there were no formal sample size calculations to assess safety of the procedure, with a sample size of 70 participants, an adverse event rate, for example of 2.5%, can be detected with a probability of 0.83 for the fecal transplantation group.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5N 1Y7
- University Health Network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Laboratory or pathology-confirmed diagnosis of recurrent C. difficile infection (CDI) with symptoms within the previous 60 days. Recurrent CDI is defined as:
- >/=2 episodes of CDI. Eligible patients must have had at least one treatment course with oral vancomycin (minimum 10 days of 500 mg total daily oral vancomycin).
Symptoms of CDI include:
- Diarrhea (see below) OR
- Abdominal pain AND abdominal distension/bloating AND fever, systemic illness with no other reason for these symptoms
Diarrhea will be self-reported and is defined as:
- at least 6 watery feces in 36 hours OR
- 3 unformed feces in 24 hours for minimum 2 days OR
8 unformed feces over 48 hours
- Age 18 years or older
- Signed informed consent
- Able to travel to clinic for follow-up visit and/or adhere to study procedures
- Agrees to abstain from taking probiotic supplementations for medicinal reasons for the duration of the study and follow-up period. To clarify, dietary intake is acceptable (e.g. non-supplemented yogurt).
Exclusion Criteria:
- Planned participation in another clinical trial
- Patients with conditions such as neutropenia, graft versus host disease or severe immunocompromise, in whom enemas are contraindicated
More than one episode of CDI that has been severe or rapid in onset, resulting in:
- intensive care unit admission
- Evidence of active, severe colitis (ie. ongoing diarrhea not responsive to oral vancomycin; hemorrhagic colitis) such that an enema is contraindicated (note that such patients may be eligible once their colitis is under control)
- Unable to tolerate fecal transplantation procedure for any other reason
- Hypersensitivity or intolerance to oral vancomycin
- Patients with underlying chronic gastrointestinal diseases that cause diarrhea, such as:
- Inflammatory bowel disease
- Short gut syndrome
- Severe motility disorders
- Severe diverticular disease
- Other chronic diarrhea NYD
- Unable to record frequency of bowel movements
- Receiving an investigational medication
- Planned therapy in the next 120 days that may cause diarrhea (example: chemotherapy)
- Planned surgery requiring perioperative antibiotics within 120 days
- Pregnancy
- Requires the regular use of medications that affect bowel motility before onset of CDI (example: metoclopramide, narcotics, loperamide)
- Serious bleeding disorder, anticoagulant use that cannot be stopped temporarily for procedure (in consultation with prescribing physician) or serious platelet disorder (platelet counts below 50).
- Any condition that, in the opinion of the investigator, would pose a health risk to the subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fecal Transplant
2 weeks of oral vancomycin pre-treatment followed by single dose fecal transplant administered by rectal enema.
Fecal transplant (slurry) consists of 50 grams healthy donor stool blended in 500ml of Normal Saline.
|
Fecal slurry 50 grams stool in 500ml normal saline
|
Active Comparator: Oral Vancomycin Taper
2 weeks of oral vancomycin pre-treatment followed by 6-week taper of oral vancomycin
|
Oral Vancomycin: Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A Randomized Controlled Trial of Oral Vancomycin Followed by Fecal Transplantation versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection.
Time Frame: 3 years
|
To assess the number of patients with recurrence of laboratory-confirmed CDI in the 120 days following completion of intervention with either oral vancomycin followed by fecal transplantation or a 6-week taper of oral vancomycin.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A Randomized Controlled Trial of Oral Vancomycin Followed by Fecal Transplantation versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection.
Time Frame: 3 years
|
To evaluate the safety profile of fecal transplantation. To characterize other outcomes of patients treated with fecal transplantation and oral vancomycin, as determined by the following: i. Early (within 14 days of treatment completion) and late (within 120 days of treatment) recurrence of symptoms compatible with CDI; ii. Days with diarrhea in the 120 days post-treatment; iii. CDI requiring hospital admission in the 120 days after treatment onset; iv. All-cause and CDI-attributable mortality; v. Recurrence of CDI in the 120 days after crossover to the alternate treatment arm. |
3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Susy Hota, MD FRCPC, Infectious Disease, Infection Prevention and Control, Epidemiologist
- Study Director: Susan Poutanen, MD MPH FRCPC, Infectious Disease, Microbiologist
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UHN # 08-0440
- 9424-U0288/2-25C 124081 (Other Identifier: Health Canada)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Clostridium Difficile Infection
-
Mikrobiomik Healthcare Company S.L.CompletedRecurrent Clostridium Difficile Infection | Primary Clostridium Difficile InfectionSpain
-
University of PecsNot yet recruitingClostridium Difficile Infection | Recurrent Clostridium Difficile InfectionHungary
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
Finch Research and Development LLC.Medpace, Inc.CompletedClostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal TransplantUnited States, Canada
-
University of PennsylvaniaTerminatedRecurrent Clostridium Difficile InfectionUnited States
-
Bio-K Plus International Inc.Sprim Advanced Life SciencesSuspendedRecurrent Clostridium Difficile InfectionUnited States
-
University of MinnesotaRecruitingRecurrent Clostridium Difficile Infection | Fecal Microbiota TransplantUnited States
-
Rebiotix Inc.CompletedRecurrent Clostridium Difficile InfectionUnited States
-
The University of Texas Health Science Center,...TerminatedRecurrent C. Difficile InfectionUnited States
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
Clinical Trials on Fecal Transplant
-
Boston Medical CenterBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts...TerminatedCrohn's DiseaseUnited States
-
Hvidovre University HospitalOdense University Hospital; University of Copenhagen; Psychiatric Center BallerupRecruitingAnorexia Nervosa | Microbiome DysbiosisDenmark
-
Beth Israel Deaconess Medical CenterBrigham and Women's Hospital; The Broad FoundationCompletedCrohn's DiseaseUnited States
-
Massachusetts General HospitalCompletedClostridium Difficile InfectionUnited States
-
VA Office of Research and DevelopmentCompleted
-
Washington University School of MedicineUniversity of Pennsylvania; Duke University; Centers for Disease Control and... and other collaboratorsCompleted
-
Mayo ClinicCompleted
-
Oulu University HospitalTurku University Hospital; University of Turku; University of Helsinki; University... and other collaboratorsNot yet recruitingCesarean Section | Overweight and Obesity | Fecal Microbiota Transplantation
-
Jasmohan BajajOpenBiomeCompletedHepatic Encephalopathy | CirrhosisUnited States
-
The University of Hong KongNot yet recruitingFecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae (FMT)Fecal Microbiota Transplantation | Carbapenem-Resistant Enterobacteriaceae Infection